Status:
COMPLETED
Effectiveness of Rehabilitation in Adults Suffering From Persistent Concussion Symptoms
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
NeuroCatch Inc.
Conditions:
Postconcussion Syndrome
Mild Traumatic Brain Injury
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
Protocol Summary The present study was developed to better understand the effects and benefits of individualizing rehabilitative treatments based on subgroup classifications determined by a standardi...
Detailed Description
Background and Rationale Disabilities secondary to traumatic brain injury are a major source of burden. Numerous treatments have been utilized and studied in an attempt to treat persistent postconcus...
Eligibility Criteria
Inclusion
- 21-years and older
- meet the definition of postconcussion syndrome, which requires a participant to report any 3 symptoms or more (from an inclusive list of 40 most commonly reported persisting symptoms) lasting at least 1-month following the diagnosis of a concussion. Concussion was defined according to the 5th International Consensus Statement on Concussion in Sport.
- Have adequate language skills in English to read and take part in rehabilitation treatment program.
Exclusion
- In-patients at Toronto Rehabilitation Institute or any other affiliated University Health Network clinics.
- Participants will be excluded should their clinical examination be unremarkable for objective physical impairments,
- Have a chronic infectious disease,
- Uncontrolled hypertension,
- Other neurological disorders (not attributed to their primary diagnosis),
- Cancer treatment (other than basal cell carcinoma), craniotomy, or refractory subdural hematoma long-term use of psychoactive medications that would compromise their ability to comprehend and perform study activities, those with pacemakers or elevated cardiovascular risk,
- Ongoing litigation surrounding their injury,
- Have been diagnosed with a moderate or severe brain injury prior to enrolment, post-concussive symptoms persisting beyond 12-months.
Key Trial Info
Start Date :
January 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 22 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06069700
Start Date
January 30 2023
End Date
April 22 2025
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto Rehabilitation Institute
Toronto, Ontario, Canada, M5G 2A2